Journal of Toxicology
Volume 2009 (2009), Article ID 530279, 16 pages
doi:10.1155/2009/530279
Research Article

Molecular and Biochemical Effects of a Kola Nut Extract on Androgen Receptor-Mediated Pathways

Rajasree Solipuram,1 Sowmya Koppula,1 Angela Hurst,1,2 Kinesha Harris,1,2 Srivatcha Naragoni,1 Krystal Fontenot,2 and Wesley Gray1,2

1Department of Environmental Toxicology, Southern University and A&M College, P.O. Box 9264, 108 Fisher Hall, Baton Rouge, LA 70813, USA
2Department of Chemistry, Southern University and A&M College, P.O. Box 9716, 116 Lee Hall, Baton Rouge, LA 70813, USA

Received 9 March 2008; Accepted 5 June 2008

Academic Editor: Margaret James

Copyright © 2009 Rajasree Solipuram et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Society, A. C., “Cancer Fact and Figures 2007,” American Cancer Society, 2007.
  2. H. Adlercreutz, “Western diet and Western diseases: some hormonal and biochemical mechanisms and associations,” The Scandinavian Journal of Clinical & Laboratory Investigation, vol. 50, pp. 3–23, 1990. View at Publisher · View at Google Scholar
  3. H. Adlercreutz, H. Markkanen, and S. Watanabe, “Plasma concentrations of phyto-oestrogens in Japanese men,” The Lancet, vol. 342, no. 8881, pp. 1209–1210, 1993. View at Publisher · View at Google Scholar
  4. M. Hedelin, Å. Klint, E. T. Chang, et al., “Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study,” Cancer Causes & Control, vol. 17, no. 2, pp. 169–180, 2006 (Swedish). View at Publisher · View at Google Scholar · View at PubMed
  5. D. C. Knight and J. A. Eden, “A review of the clinical effects of phytoestrogens,” Obstetrics & Gynecology, vol. 87, no. 5, part 2, pp. 897–904, 1996.
  6. F. O. Stephens, “Phytoestrogens and prostate cancer: possible preventive role,” The Medical Journal of Australia, vol. 167, no. 3, pp. 138–140, 1997.
  7. A. J. Blumenfeld, N. Fleshner, B. Casselman, and J. Trachtenberg, “Nutritional aspects of prostate cancer: a review,” The Canadian Journal of Urology, vol. 7, no. 1, pp. 927–935, discussion 936, 2000.
  8. E. P. Castle and J. B. Thrasher, “The role of soy phytoestrogens in prostate cancer,” Urologic Clinics of North America, vol. 29, no. 1, pp. 71–81, 2002. View at Publisher · View at Google Scholar
  9. H. Adlercreutz, “Epidemiology of phytoestrogens,” Baillière's Clinical Endocrinology and Metabolism, vol. 12, no. 4, pp. 605–623, 1998. View at Publisher · View at Google Scholar
  10. K. Griffiths, L. Denis, A. Turkes, and M. S. Morton, “Phytoestrogens and diseases of the prostate gland,” Baillière's Clinical Endocrinology and Metabolism, vol. 12, no. 4, pp. 625–647, 1998. View at Publisher · View at Google Scholar
  11. M. Pollard, “Prevention of prostate-related cancers in Lobund-Wistar rats,” The Prostate, vol. 39, no. 4, pp. 305–309, 1999. View at Publisher · View at Google Scholar
  12. M. Pollard and W. Wolter, “Prevention of spontaneous prostate-related cancer in lobund-Wistar rats by a soy protein isolate/isoflavone diet,” The Prostate, vol. 45, no. 2, pp. 101–105, 2000. View at Publisher · View at Google Scholar
  13. S. S. Strom, Y. Yamamura, C. M. Duphorne, et al., “Phytoestrogen intake and prostate cancer: a case-control study using a new database,” Nutrition and Cancer, vol. 33, no. 1, pp. 20–25, 1999.
  14. J. Geller, L. Sionit, C. Partido, et al., “Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture,” The Prostate, vol. 34, no. 2, pp. 75–79, 1998. View at Publisher · View at Google Scholar
  15. K. S. Weber, N. A. Jacobson, K. D. Setchell, and E. D. Lephart, “Brain aromatase and 5α-reductase, regulatory behaviors and testosterone levels in adult rats on phytoestrogen diets,” Proceedings of the Society for Experimental Biology and Medicine, vol. 221, no. 2, pp. 131–135, 1999. View at Publisher · View at Google Scholar
  16. K. S. Weber, K. D. Setchell, D. M. Stocco, and E. D. Lephart, “Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5α-reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague-Dawley rats,” Journal of Endocrinology, vol. 170, no. 3, pp. 591–599, 2001. View at Publisher · View at Google Scholar
  17. M. Hedelin, K. A. Bälter, E. T. Chang, et al., “Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer,” The Prostate, vol. 66, no. 14, pp. 1512–1520, 2006. View at Publisher · View at Google Scholar · View at PubMed
  18. P. O. Osadebe, G. B. Okide, and I. C. Akabogu, “Study on anti-diabetic activities of crude methanolic extracts of Loranthus micranthus (Linn.) sourced from five different host trees,” Journal of Ethnopharmacology, vol. 95, no. 2-3, pp. 133–138, 2004. View at Publisher · View at Google Scholar · View at PubMed
  19. M. Kamatenesi-Mugisha and H. Oryem-Origa, “Traditional herbal remedies used in the management of sexual impotence and erectile dysfunction in western Uganda,” African Health Sciences, vol. 5, no. 1, pp. 40–49, 2005.
  20. D. Robertson, Jamaican Herbs: Nutritional and Medicinal Values, Vol. 1, Jamaican Herbs, Kingston, Jamaica, 1988.
  21. “Jamaican Bush Teas,” 2006, http://www.Jamaican-Recipes.com.
  22. K. Fontenot, S. Naragoni, M. Claville, and W. Gray, “Characterization of Bizzy Nut extracts in estrogen-responsive MCF-7 breast cancer cells,” Toxicology and Applied Pharmacology, vol. 220, no. 1, pp. 25–32, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. Applied Biosystems, ABI PRISM 7700 Sequence Detection System User Bulletin #2, 2001.
  24. I. Anderson, C. R. Bartley, R. A. Lerch, W. G. N. Gray, P. D. Friesen, and J. Gorski, “Estrogen receptor α requires no accessory factors for high-affinity binding to a consensus response element,” Biochemistry, vol. 37, no. 49, pp. 17287–17298, 1998. View at Publisher · View at Google Scholar · View at PubMed
  25. W. G. N. Gray, E. E. Biswas, N. Bashirelahi, and S. B. Biswas, “A low-affinity estrogen-binding site in pregnant rat uteri: analysis and partial purification,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 24, pp. 11502–11506, 1994. View at Publisher · View at Google Scholar
  26. W. B. Panko, C. S. Watson, and J. H. Clark, “The presence of a second, specific estrogen binding site in human breast cancer,” Journal of Steroid Biochemistry, vol. 14, no. 12, pp. 1311–1316, 1981.
  27. Y.-C. Cheng and W. H. Prusoff, “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction,” Biochemical Pharmacology, vol. 22, no. 23, pp. 3099–3108, 1973. View at Publisher · View at Google Scholar
  28. S. Stahl, T.-Y. Chun, and W. G. Gray, “Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line,” Toxicology and Applied Pharmacology, vol. 152, no. 1, pp. 41–48, 1998. View at Publisher · View at Google Scholar · View at PubMed
  29. W. Washington, L. Hubert, D. Jones, and W. G. Gray, “Bisphenol A binds to the low-affinity estrogen binding site,” In Vitro & Molecular Toxicology, vol. 14, no. 1, pp. 43–51, 2001. View at Publisher · View at Google Scholar · View at PubMed
  30. GraphPad Prism version 3.0 for Windows, GraphPad Software, San Diego, Calif, USA, http://www.graphpad.com.
  31. K. Noguchi, H. Uemura, M. Harada, et al., “Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist,” International Journal of Clinical Oncology, vol. 6, no. 1, pp. 29–33, 2001. View at Publisher · View at Google Scholar
  32. T. V. Nguyen, M. Yao, and C. J. Pike, “Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection,” Endocrinology, vol. 148, no. 6, pp. 2936–2943, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. L. Yu, G. L. Blackburn, and J.-R. Zhou, “Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells,” The Journal of Nutrition, vol. 133, no. 2, pp. 389–392, 2003.
  34. H.-G. Yoon and J. Wong, “The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor,” Molecular Endocrinology, vol. 20, no. 5, pp. 1048–1060, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. P. S. Nelson, N. Clegg, H. Arnold, et al., “The program of androgen-responsive genes in neoplastic prostate epithelium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11890–11895, 2002. View at Publisher · View at Google Scholar · View at PubMed
  36. P. Soronen, M. Laiti, S. Törn, et al., “Sex steroid hormone metabolism and prostate cancer,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 92, no. 4, pp. 281–286, 2004. View at Publisher · View at Google Scholar · View at PubMed
  37. T. L. Parker, D. L. Eggett, and M. J. Christensen, “Estrogen receptor activation and estrogen-regulated gene expression are unaffected by methylseleninic acid in LNCaP prostate cancer cells,” The Journal of Nutritional Biochemistry, vol. 18, no. 11, pp. 746–752, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. J. Veldscholte, C. A. Berrevoets, C. Ris-Stalpers, et al., “The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 41, no. 3–8, pp. 665–669, 1992. View at Publisher · View at Google Scholar
  39. D. Yin, W. Gao, J. D. Kearbey, et al., “Pharmacodynamics of selective androgen receptor modulators,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 3, pp. 1334–1340, 2003. View at Publisher · View at Google Scholar · View at PubMed
  40. C. Gill, S. E. Walsh, C. Morrissey, J. M. Fitzpatrick, and R. W. G. Watson, “Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms,” The Prostate, vol. 67, no. 15, pp. 1641–1653, 2007. View at Publisher · View at Google Scholar · View at PubMed
  41. H. T. Le, C. M. Schaldach, G. L. Firestone, and L. F. Bjeldanes, “Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells,” Journal of Biological Chemistry, vol. 278, no. 23, pp. 21136–21145, 2003. View at Publisher · View at Google Scholar · View at PubMed
  42. M. Bonham, H. Arnold, B. Montgomery, and P. S. Nelson, “Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma,” Cancer Research, vol. 62, no. 14, pp. 3920–3924, 2002.
  43. N. B. Kumar and K. Besterman-Dahan, “Nutrients in the chemoprevention of prostate cancer: current and future prospects,” Cancer Control, vol. 6, no. 6, pp. 580–586, 1999.
  44. F. H. Sarkar and Y. Li, “Mechanisms of cancer chemoprevention by soy isoflavone genistein,” Cancer and Metastasis Reviews, vol. 21, no. 3-4, pp. 265–280, 2002. View at Publisher · View at Google Scholar
  45. J. M. Holzbeierlein, J. McIntosh, and J. B. Thrasher, “The role of soy phytoestrogens in prostate cancer,” Current Opinion in Urology, vol. 15, no. 1, pp. 17–22, 2005. View at Publisher · View at Google Scholar